Literature DB >> 21665179

Molecular characterization of a t(2;7) translocation linking CDK6 to the IGK locus in CD5(-) monoclonal B-cell lymphocytosis.

Edward Parker1, Jeffrey R Macdonald, Chen Wang.   

Abstract

The term monoclonal B-cell lymphocytosis (MBL) is used to characterize individuals with a circulating population of clonal B-cells and no other features of a lymphoproliferative disorder. Although several recent studies have examined the molecular basis of this condition, the subgroup of MBL lacking CD5 expression has been largely overlooked. In this study, we sequenced a t(2;7) in a patient with persistent but non-progressing CD5(-) MBL. This revealed a breakpoint at 2p11.2 localized to the recombination signal sequence (RSS) of the immunoglobulin κ (IGK) variable gene IGKV3-15, and a breakpoint at 7q21.2 located 520 base pairs (bp) upstream of the transcription start site of cyclin-dependent kinase 6 (CDK6 ). The 7q breakpoint showed perfect sequence homology to the immunoglobulin RSS heptamer, and was located within 3 bp of a t(2;7) junction previously characterized in splenic marginal zone lymphoma (SMZL). These findings highlight a genetic link between CD5(-) MBL and SMZL, and implicate the dysregulation of CDK6 in the emergence of this preclinical disorder. 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21665179     DOI: 10.1016/j.cancergen.2011.03.004

Source DB:  PubMed          Journal:  Cancer Genet


  3 in total

1.  Prevalence and Immunophenotypic Characteristics of Monoclonal B-Cell Lymphocytosis in Healthy Korean Individuals With Lymphocytosis.

Authors:  In Young Yoo; Sung Hoan Bang; Dae Jin Lim; Seok Jin Kim; Kyunga Kim; Hee Jin Kim; Sun-Hee Kim; Duck Cho
Journal:  Ann Lab Med       Date:  2020-09       Impact factor: 3.464

2.  Treatment of splenic marginal zone lymphoma of the CNS with high-dose therapy and allogeneic stem cell transplantation.

Authors:  Christoph Busemann; Andrej Gudzuhn; Carsten Hirt; Michael Kirsch; Silke Vogelgesang; Christian A Schmidt; Gottfried Dölken; William H Krüger
Journal:  Exp Hematol Oncol       Date:  2012-10-16

Review 3.  Treating cancer with selective CDK4/6 inhibitors.

Authors:  Ben O'Leary; Richard S Finn; Nicholas C Turner
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.